



## Transparency Reporting at Kyowa Kirin UK LTD and KYOWA KIRIN International Methodological Note for 2024 data

### 1. Introduction

Kyowa Kirin Ltd (KKL) and Kyowa Kirin International PLC (KKI) are committed to improving patient care through the delivery of targeted therapies and specialised support services in the UK and Republic of Ireland, helping to drive better health outcomes in the communities we serve.

We do this through engagement with our stakeholders and where appropriate through the provision of financial and non-financial support to Healthcare Organisations (HCOs), Patient Organisations (POs), or Healthcare Professionals (HCPs) and their engagement and payment for a range of purposes, including but not limited to activities that support the improvement of patient care.

Provision of support and payments for services are referred to as ‘Transfers of Value’ (ToVs). In accordance with [The Association of The British Pharmaceutical Industry \(ABPI\) Code of Practice](#) and [The Irish Pharmaceutical Healthcare Association \(IPHA\) Code of Practice](#) Kyowa Kirin Ltd and Kyowa Kirin International PLC collectively publish details of ToVs to these individuals and organisations on an annual basis (<https://kyowakirininternational.com/who-we-are/responsibility/>).

Each Kyowa Kirin affiliate in Europe is accountable for capturing and validating ToV data in their country, and one disclosure is made per sovereign state. This disclosure covers ToVs between 1<sup>st</sup> January 2024 to 31<sup>st</sup> December 2024 to HCPs and HCOs which are registered in the UK and The Republic of Ireland and officially allowed to practice or operate in those regions.

### 2. Scope of disclosure

This disclosure includes the following ToVs:

EFPIA* Category	EFPIA sub-category	Examples
Donations and grants	Donations and Grants	<ul style="list-style-type: none"> <li>• Donations to HCOs</li> <li>• Donations and Grants to Patient Organisations</li> <li>• Educational grants</li> <li>• Investigator- Sponsored Studies</li> </ul>
Contribution to cost of events	Sponsorship agreements	Sponsorship of educational congresses organised by HCOs or third parties on their behalf
	Event Registration fees	Reimbursement to HCPs of costs of registration to attend events, such as congresses or scientific conferences
	Travel and accommodation	Reimbursement to HCPs of costs to facilitate travel and accommodation expenses to attend congresses
	Subsistence (UK only)	Subsistence costs that have taken place during a third party event that has been supported by KKI in the UK. The named benefactor is the HCO and not the individual beneficiary HCP.
Fees for service to HCPs (Please note, payments for contracted services with HCPs are disclosed in a manner where the benefactor is named)	Fees	<ul style="list-style-type: none"> <li>• Chairing or attending Advisory Boards (patients may also participate to provide their valuable perspectives on living with specific conditions)</li> <li>• Speaking engagements;</li> </ul>

		<ul style="list-style-type: none"> <li>Medical writing (We may engage HCPs to create content that raises awareness and educates the public about healthcare topics).</li> </ul>
	Related expenses	Travel and accommodation expenses relating to the activities above
Fees for service to members of the public (journalists and patients) NB. Payments for contracted services with members of the public are disclosed in an aggregated and anonymised manner	Fees and related expenses	Activities such as: <ul style="list-style-type: none"> <li>Attending Advisory Boards;</li> <li>Speaking engagements</li> </ul>
Research and Development	Research and Development	Activities relating to: <ul style="list-style-type: none"> <li>the planning or conduct of clinical studies;</li> <li>clinical trials;</li> <li>non-interventional studies that are prospective in nature;</li> <li>clinical investigators' meetings</li> </ul>

\* European Federation of Pharmaceutical Industries & Associations ([EFPIA Homepage](#))

If activities relate to retrospective non-interventional studies, related ToVs are included in Fees for Service, rather than Research and Development.

This disclosure excludes the following ToVs:

- Informational and educational materials and items of medical utility, in line with article 9 of the EFPIA HCP/HCO Disclosure Code
- Logistical costs related to KKI-organised meetings (e.g. room hire)

As The Association of The British Pharmaceutical Industry (ABPI) Code of Practice and The Irish Pharmaceutical Healthcare Association (IPHA) Code of Practice only relates to ToVs to HCPs and HCOs, this disclosure does not include:

- Donations to non-HCOs

Some HCPs continue to provide advice to the healthcare community and pharma industry after they have retired. Generally, KKI includes such HCPs in the applicable regulation's definition of an HCP, however this depends on their role and ability to prescribe and influence.

### 3. Date of ToVs

The date of the ToVs included in this disclosure is the date of bank transfer.

### 4. Direct and Indirect ToVs

For direct ToVs, the recipient is considered to be the person or entity holding the bank account receiving the money.

Kyowa Kirin Ltd and Kyowa Kirin International PLC also provide indirect ToVs. Payments that are made through Clinical Research Organisations are included under Research and Development and aggregated. Where a third party has been appointed by an HCO to manage an event, and where the HCO benefits from the ToV, the ToV is disclosed against the HCO. Where third parties are appointed by KKI to make travel and accommodation arrangements for HCPs, the ToVs are reported against the HCP who received the benefit.

### 5. Cross-border activities

KKI makes best efforts to capture and report all ToVs to HCPs, POs and HCOs with primary practice in a country with EFPIA Disclosure Code or other transparency reporting requirements.



The country of disclosure is based on the HCP's country of principal practice, the HCO's country of registration or the country where the PO has a bank account.

## 6. Legal Basis to Process Personal Data

Kyowa Kirin Ltd and Kyowa Kirin International PLC apply Legitimate Interest as the legal basis to process personal data. Legitimate Interest comprises of our legitimate business need to comply with industry codes such as EFPIA, ABPI and IPHA and ensure transparency while at the same time to be able to promote trust and transparency with the people we work. In practice, this means that we do not ask for consent/permission to publish the information with the value received on our website.

However, we still have a responsibility to allow HCPs the opportunity to raise objections using the email address: [kki\\_compliance\\_northerncluster@kyowakirin.com](mailto:kki_compliance_northerncluster@kyowakirin.com). Where an objection is raised, and a reasonable rationale is provided, then the ToV may be disclosed in an aggregated manner if considered appropriate.

ToVs within scope of disclosure are provided in a manner that names the beneficiary, place of work, nature and purpose and amount paid. Payments to HCOs are reported in the same manner as they are legal entities.

## 7. Disclosure

Our report of ToVs in 2024 is published on <https://kyowakirininternational.com/who-we-are/responsibility/> in English.

The currency used for disclosure is Sterling for the UK and Euro for The Republic of Ireland. In the case that payments are made in a currency other than the reporting currency the payment amount is converted to the reporting currency using the daily exchange rate between the two currencies on the day of payment. All ToVs include VAT where applicable.

Any questions regarding this disclosure should be directed to [kki\\_compliance\\_northerncluster@kyowakirin.com](mailto:kki_compliance_northerncluster@kyowakirin.com)